Compare ACET & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACET | FBIO |
|---|---|---|
| Founded | 1947 | 2006 |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 78.3M |
| IPO Year | 2017 | N/A |
| Metric | ACET | FBIO |
|---|---|---|
| Price | $7.73 | $2.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $48.33 | $17.00 |
| AVG Volume (30 Days) | 136.8K | ★ 448.7K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.22 |
| Revenue Next Year | N/A | $40.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.62 |
| 52 Week High | $9.05 | $4.53 |
| Indicator | ACET | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 32.80 |
| Support Level | $6.28 | $2.20 |
| Resistance Level | $8.46 | $2.71 |
| Average True Range (ATR) | 0.47 | 0.11 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 57.30 | 1.79 |
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.